La tunisie Medicale - 2022 ; Vol 100 ( n°01 ) : 37-43
[ 761 times seen ]
Summary

Introduction: The link between gastric mucosa-associated lymphoid tissue lymphoma (LG-MALT) and chronic Helicobacter Pylori (HP) infection had led to a real revolution in the management of the disease.
Aims: To study the results of the HP eradication therapy and to clarify its place in the tumor response.
Methods: A descriptive retrospective bicentric study, between January 2007 and December 2016, including patients with LG-MALT treated in the gastroenterology departments of Sahloul hospital in Sousse and Habib Bougtafa hospital in Bizerte, and having received treatment for eradication of HP.
Results: Sixty-three patients were included. The male/female sex ratio was 1.42. The average age was 58 years. The symptomatology was dominated by epigastric pain (96.8%). On digestive endoscopy, the most frequent location and appearance were gastric antrum (39.6%) and ulcerations (89%). The lymphoma was classified as stage IE and IIE1 in 81% and 19% of cases, respectively. The HP status was positive in all patients. The HP eradication rate was 82.5% after three anti-HP treatment courses. Complete remission of lymphoma was obtained in 81% of patients at 18 months. Non-response to HP eradication therapy was observed in 19% of patients. Non-responder patients had a longer diagnostic delay (p=0.02), more diffuse endoscopic involvement (p=0.001) and a more frequent appearance of large gastric folds (p=0.001).
Conclusion: The course of LG-MALT is determined by the treatment for the eradication of HP. Its success promotes remission of lymphoma.

Key - Words
Article
Reference
  1. Ruskone-Fourmestraux A. Lymphome gastrique. Rev Prat 1997;47:848-54.
  2. Severson RK, Davis S. increasing incidence of primary gastric lymphoma. Cancer 1990;66(6):1283- 7. doi: 10.1002/1097-0142(19900915)66:6<1283::aidcncr2820660631>3.0.co;2-4.
  3. Ducreux M, Boutron MC, Piard F, Carli PM, Faivre J. A 15-years series of gastrointestinal non-Hodgkin’s lymphomas: a population-based study. Br J Cancer 1998;77(3):511-4. doi: 10.1038/bjc.1998.82.
  4. Gurney KA, Cartwright RA, Gilman EA. Descriptive epidemiology of gastrointestinal non-Hodgkin’s lymphoma in a population-based registry. Br J Cancer 1999;79(11- 12):1929-34. doi: 10.1038/sj.bjc.6690307.
  5. Caletti G, Fusaroli P, Togliani T. EUS in MALT lymphoma. Gastrointest Endosc. 2002;56(4, Supplement):S21-6. doi: 10.1016/s0016-5107(02)70081-3.
  6. Fusaroli P, Buscarini E, Peyre S, et al. Interobserver agreement in staging gastric malt lymphoma by EUS. Gastrointest Endosc. 2002;55(6):662-8. doi: 10.1067/ mge.2002.123421.
  7. Lehours P, Mégraud F. Infections à Helicobacter pylori et lymphome gastrique du MALT. Antibiotiques. 2005;7(2):97- 105. https://doi.org/10.1016/S1294-5501(05)80174-8.
  8. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment. Gut. 2001;48(3):297- 303. doi: 10.1136/gut.48.3.297.
  9. Georges Delsol. Classification OMS 2008 des lymphomes. Annales de pathologie (2008) 28S, S20—S24. Doi : 10.1016/j.annpat.2008.09.002.
  10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31(11):1860-1.
  11. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection--the Maastricht IV. Gut. 2012;61 (5):646-64. doi: 10.1136/gutjnl-2012-302084.
  12. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/ gutjnl-2016-312288. Epub 2016 Oct 5.
  13. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for posttreatment evaluation of gastric MALT lymphoma. Gut. 2003 Nov;52(11):1656. doi: 10.1136/gut.52.11.1656.
  14. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi 144-8. doi: 10.1093/annonc/mdt343.
  15. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61(5):646–64. doi: 10.1136/ gutjnl-2012-302084.
  16. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212– 238. doi: 10.1038/ ajg.2016.563.
  17. Ben Mansour K, Burucoa C, Zribi M, et al. Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Ann Clin Microbiol Antimicrob. 2010;9:22. doi: 10.1186/1476-0711-9-22.
  18. Loghmari H, Bdioui F, Bouhlel W, et al. Comparaison de 2 protocoles de trithérapie anti-hélicobacter pylori incluant clarithromycine versus métronidazole. Étude prospective randomisée de 85 cas. La tunisie Medicale. 2012 ; 90(1):31–35.
  19. Moalla M, Chtourou L, Smaoui H, et al. Primary resistance of helicobacter pylori to clarithromycin in Tunisia. 29th United European Gastroenterology Week 2021 Poster Presentations. UEG journal 2021 october;9(S8):334. Available from: onlinelibrary.wiley.com/journal/20506414.
  20. Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa– Associated Lymphoid Tissue Lymphoma. Clin GastroenterolHepatol. 2010;8(2):105-10. doi: 10.1016/j.cgh.2009.07.017.
  21. Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter pylori and gastric MALT lymphoma. Gut 2002; 50(Suppl. 3):III19–24. doi: 10.1136/gut.50.suppl_3.iii19.
  22. Matysiak-Budnik T, Fabiani B, Hennequin C, et al. Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). Dig Liver Dis. 2018;50(2):124-31. doi: 10.1016/j.dld.2017.12.006.
  23. Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol WJG. 2007;13(26):3554- 66. doi: 10.3748/wjg.v13.i26.3554.
  24. Wundisch T, Thiede C, Morgner A, et al. Long-Term FollowUp of Gastric MALT Lymphoma After Helicobacter Pylori Eradication. J Clin Oncol. 2005; 23(31):8018-24. doi: 10.1200/JCO.2005.02.3903.
  25. Mendes LST, Attygalle AD, Wotherspoon AC. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation. Gut. 2014;63(9):1526-7. doi: 10.1136/gutjnl-2014-307389.
  26. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: A clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97(10):2462‑73. doi: 10.1002/cncr.11415.
  27. Varas MJ, Fabra R, Abad R, et al. Endoscopic staging of lowgrade gastric MALT lymphoma. Rev Esp EnfermDig .2006; 98(3):189-95. doi: 10.4321/s1130-01082006000300005.
  28. Kim JS, Chung SJ, Choi YS, et al. Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer. 2007; 96(9):1324‑8. doi: 10.1038/sj.bjc.6603708.
  29. Sorrentino D, Ferraccioli GF, Labombarda A, et al. Helicobacter pylori, gastric MALT and B-cell clonality. Clin Exp Rheumatol. 1996;14 Suppl 14:S51-4.
  30. Fischbach W, Goebeler-Kolve M-E, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53(1):34-7. doi: 10.1136/gut.53.1.34.
  31. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507-13. doi: 10.1136/ gutjnl-2011-300495.
  32. Toyoda K, Maeshima AM, Nomoto J, et al. Mucosaassociated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results. Ann Hematol. 2019;98(7):1675-1687. doi: 10.1007/s00277-019-03671-5.
  33. Raderer M, Streubel B, Wöhrer S, Häfner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006;55(5):616-8. doi: 10.1136/gut.2005.083022. Epub 2005 Nov 18.
  34. 3Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastricextranodal marginal zone B-celllymphoma of MALT. Gut. 2011;60(6):747-58. doi: 10.1136/gut.2010.224949. Epub 2011 Feb 11.
  35. Levy M, Copie-Bergman C, Traulle C, et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa- associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol. 2002;97(2):292- 7. doi: 10.1111/j.1572-0241.2002.05460.x.
  36. Ryu KD, Kim GH, Park SO, et al. Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A SingleCenter Experience. Gut Liver. 2014;8(4):408-14. doi: 10.5009/gnl.2014.8.4.408. Epub 2013 Dec 24.
Login
E-mail :
Password :
Remember Me Forgot password? Sign UP
Archives
2022
January
February
March
April
May
June
July
August
September
October
November
December
Keywords most used
Child treatment surgery diagnosis Tunisia prognosis Children Crohn’s disease Breast cancer Cancer screening epidemiology Ulcerative colitis mammography Risk factors
Newsletter
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !